References
- Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab. Vasc. Dis. Res.2, 26–23 (2005).
- Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab. Vasc. Dis. Res.7, 251–259 (2010).
- Ferreiro JL, Cequier ÁR, Angiolillo DJ. Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diab. Vasc. Dis. Res.7, 274–288 (2010).
- Krempf M, Parhofer KG, Steg PG et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the Reduction of Atherothrombosis for Continued Health [REACH] Registry). Am. J. Cardiol.105, 667–671 (2010).
- Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol.49, 1982–1988 (2007).
- Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38. Circulation118, 1626–1636 (2008).
- American Diabetes Association. Standards of Medical Care in Diabetes – 2009. Diabetes Care32(S1), S13–S61 (2009).
- American Diabetes Association. Standards of Medical Care in Diabetes – 2010. Diabetes Care33(S1), S11–S61 (2010).
- De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ339, b4531 (2009).
- Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am. J. Med. Sci.341, 1–9 (2011).